Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Фиксированные комбинации ингаляционных глюкокортикостероидов/b-адреномиметиков длительного действия: реалии 2011 г.
Фиксированные комбинации ингаляционных глюкокортикостероидов/b-адреномиметиков длительного действия: реалии 2011 г.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Liu F, Liu CT. In vitro study on the mechanism of myocardial injury induced by Formoterol and the protective effect of Budesonide in rats. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2011; 27 (3): 245–8.
2. Søes-Petersen U, Kava T, Dahle R et al. Budesonide/formoterol maintenance and reliever therapy versus conventional best standard treatment in asthma in an attempted «real life» setting. Clin Respir J 2011; 5 (3): 173–82; doi: 10.1111/j.1752-699X.2010.00217.x
3. Bateman ED, Harrison TW, Quirce S et al. Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respir Res 2011; 12: 38.
4. Braido F, Baiardini I, Compalati E et al. Towards the grade of recommendations, assessment, development and evaluation system: methods and results of budesonide/formoterol maintenance and reliever therapy research. Curr Opin Allergy Clin Immunol 2011 [Epub ahead of print].
5. Hoe S, Young PM, Traini D. Aerosol tribocharging and its relation to the deposition of OxisTM Turbuhaler® in the electrical next generation impactor. J Pharm Sci 2011[Epub ahead of print]. Doi: 10.1002/jps.22721
6. Newman SP. A Comparison of Lung Deposition Patterns Between Different Asthma Inhalers. J Aerosol Med 1995; 8 (Suppl. 3): S21–7.
7. Kanabuchi K, Kondo T, Tanigaki T et al. Minimal inspiratory flow from dry powder inhalers according to a biphasic model of pressure vs. flow relationship. Tokai J Exp Clin Med 2011; 36 (1): 1–4.
8. Pedersen S. Inspiratory capacity through the turbuhaler in various patient groups. J Aerosol Med 1994; 7 (Suppl. 1): S55–8.
9. Lee SM, Chang YS, Kim CW et al. Skills in handling turbuhaler, diskus, and pressurized metered-dose inhaler in korean asthmatic patients. Allergy Asthma Immunol Res 2011; 3 (1): 46–52.
10. Basheti IA, Qunaibi E, Bosnic-Anticevich SZ et al. Investigation of Errors in Accuhaler and Turbuhaler Technique by Asthma Patients and Pharmacists from Jordan and Australia. Respir Care 2011 [Epub ahead of print].
11. Nikander K, Turpeinen M, Pelkonen AS et al. True adherence with the Turbuhaler in young children with asthma. Arch Dis Child 2011; 96 (2): 168–73.
12. Haughney J, Aubier M, Jørgensen L et al. Comparing asthma treatment in elderly versus younger patients. Respir Med 2011; 105 (6): 838–45.
13. Wang K, Liu CT, Wu YH et al. Effects of formoterol-budesonide on airway remodeling in patients with moderate asthma. Acta Pharmacol Sin 2011; 32 (1): 126–32.
14. Sears MR, Ottosson A, Radner F, Suissa S. Long-acting {beta}-agonists. A review of formoterol safety data from asthma clinical trials. Eur Respir J 2009; 33 (1): 21–32.
15. Kemp J, Armstrong L, Wan Y et al. Safety of formoterol in adults and children with asthma: a meta-analysis. Ann Allergy Asthma Immunol 2011; 107 (1): 71–8.
2. Søes-Petersen U, Kava T, Dahle R et al. Budesonide/formoterol maintenance and reliever therapy versus conventional best standard treatment in asthma in an attempted «real life» setting. Clin Respir J 2011; 5 (3): 173–82; doi: 10.1111/j.1752-699X.2010.00217.x
3. Bateman ED, Harrison TW, Quirce S et al. Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respir Res 2011; 12: 38.
4. Braido F, Baiardini I, Compalati E et al. Towards the grade of recommendations, assessment, development and evaluation system: methods and results of budesonide/formoterol maintenance and reliever therapy research. Curr Opin Allergy Clin Immunol 2011 [Epub ahead of print].
5. Hoe S, Young PM, Traini D. Aerosol tribocharging and its relation to the deposition of OxisTM Turbuhaler® in the electrical next generation impactor. J Pharm Sci 2011[Epub ahead of print]. Doi: 10.1002/jps.22721
6. Newman SP. A Comparison of Lung Deposition Patterns Between Different Asthma Inhalers. J Aerosol Med 1995; 8 (Suppl. 3): S21–7.
7. Kanabuchi K, Kondo T, Tanigaki T et al. Minimal inspiratory flow from dry powder inhalers according to a biphasic model of pressure vs. flow relationship. Tokai J Exp Clin Med 2011; 36 (1): 1–4.
8. Pedersen S. Inspiratory capacity through the turbuhaler in various patient groups. J Aerosol Med 1994; 7 (Suppl. 1): S55–8.
9. Lee SM, Chang YS, Kim CW et al. Skills in handling turbuhaler, diskus, and pressurized metered-dose inhaler in korean asthmatic patients. Allergy Asthma Immunol Res 2011; 3 (1): 46–52.
10. Basheti IA, Qunaibi E, Bosnic-Anticevich SZ et al. Investigation of Errors in Accuhaler and Turbuhaler Technique by Asthma Patients and Pharmacists from Jordan and Australia. Respir Care 2011 [Epub ahead of print].
11. Nikander K, Turpeinen M, Pelkonen AS et al. True adherence with the Turbuhaler in young children with asthma. Arch Dis Child 2011; 96 (2): 168–73.
12. Haughney J, Aubier M, Jørgensen L et al. Comparing asthma treatment in elderly versus younger patients. Respir Med 2011; 105 (6): 838–45.
13. Wang K, Liu CT, Wu YH et al. Effects of formoterol-budesonide on airway remodeling in patients with moderate asthma. Acta Pharmacol Sin 2011; 32 (1): 126–32.
14. Sears MR, Ottosson A, Radner F, Suissa S. Long-acting {beta}-agonists. A review of formoterol safety data from asthma clinical trials. Eur Respir J 2009; 33 (1): 21–32.
15. Kemp J, Armstrong L, Wan Y et al. Safety of formoterol in adults and children with asthma: a meta-analysis. Ann Allergy Asthma Immunol 2011; 107 (1): 71–8.
Авторы
А.А.Визель
Кафедра фтизиопульмонологии КГМУ Минздравсоцразвития РФ, Казань
Кафедра фтизиопульмонологии КГМУ Минздравсоцразвития РФ, Казань
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.